Why Broadcom Stock Is Slipping Today

The Motley Fool
Updated
Mitrade
coverImg
Source: Shutterstock

After a two-session surge driven by the emergence of the chipmaker's artificial intelligence (AI) business in the fiscal fourth-quarter earnings report it delivered on Thursday, Broadcom (NASDAQ: AVGO) was pulling back Tuesday morning alongside the broader semiconductor sector.

While there wasn't any company-specific news about Broadcom, its sell-off was indicative of a larger trend. As of 11:59 a.m. ET, the stock was down 4.4%.

A stock chart going down

Image source: Getty Images.

Did Broadcom's rally go too far?

Investors seem to be debating the fair value of this stock after its post-earnings jump last week. Broadcom's results were mostly in line with analysts' consensus estimates, as was its guidance, but investors were particularly impressed with its AI-related growth. The company said its AI revenue jumped 220% in fiscal 2024 (which ended Nov. 3), and management predicted that AI revenue would grow by 65% in fiscal 2025's first quarter. It based that growth forecast on the high demand for its Jericho 3 Ethernet switches, which are designed for AI networks.

Despite investors' enthusiasm for Broadcom's AI business, a broader sense of skepticism seemed to pervade the market Tuesday. Its chip stock peers Nvidia, Arm, and Marvell were all down as well.

There wasn't a clear trigger for the sell-off, but investors seem to be worrying again that demand for AI products may not be as strong as current stock prices imply. Nvidia stock is now down four straight sessions in a row amid signs that growth in AI spending is likely to slow next year.

What it means for Broadcom

High expectations are now baked into Broadcom's stock price. It trades at a price-to-earnings ratio of nearly 50 based on adjusted earnings, and its growth rate will moderate as it laps its acquisition of VMware, which closed in November 2023.

Still, with AI-related tailwinds building for Broadcom, the stock looks fairly valued. It should be a winner over the long term.

* The content presented above, whether from a third party or not, is considered as general advice only.  This article should not be construed as containing investment advice, investment recommendations, an offer of or solicitation for any transactions in financial instruments.

goTop
quote
Do you find this article useful?
Related Articles
placeholder
Netflix Q3 Earnings Preview: Double Growth in Revenue and Profit Expected Amid Wall Street's Universal OptimismStreaming giant Netflix is set to release its Q3 2025 financial results after U.S. market close on Tuesday, October 21, with the current market sentiment largely optimistic.
Author  TradingKey
8 hours ago
Streaming giant Netflix is set to release its Q3 2025 financial results after U.S. market close on Tuesday, October 21, with the current market sentiment largely optimistic.
placeholder
Dow Jones futures rise due to easing US-China trade tensions, Fed rate cut betsDow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) regular session on Monday.
Author  FXStreet
9 hours ago
Dow Jones futures advance 0.37% to rise near 46,550 during European hours, ahead of the opening of the United States (US) regular session on Monday.
placeholder
Japan and Korea Lead Asian Stock Surge — Nikkei 225 Breaks 49,000, KOSPI Tops 3,800Asian equities rallied broadly on Monday, October 20, with Japan and South Korea setting fresh record highs.
Author  TradingKey
10 hours ago
Asian equities rallied broadly on Monday, October 20, with Japan and South Korea setting fresh record highs.
placeholder
Lilly, Novo Nordisk Shares Plummet as Trump Announces Price Cut to OzempicOn Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
Author  TradingKey
Oct 17, Fri
On Thursday, shares of Eli Lilly and Novo Nordisk fell sharply in after-hours trading after President Donald Trump announced a significant price reduction for the diabetes drug Ozempic.
placeholder
Are European Stocks Peaking? SocGen,Citi Turn Bearish on Q4, U.S. Regional Bank Crisis Adds New RiskA series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.
Author  TradingKey
Oct 17, Fri
A series of bad loan incidents in the U.S. are catalyzing a credit crisis in the banking sector, and these concerns are now spreading to Europe’s top-performing bank stocks this year.